Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
|
Jul 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia
|
Apr 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
|
Jul 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
|
Apr 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
|
Jun 2019
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
|
Jul 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Guideline-based indicators for adult patients with myelodysplastic syndromes
|
Aug 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Haploidentical transplant in patients with myelodysplastic syndrome
|
Jul 2017
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|